2.965

0.84% -0.025

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $2.965, with a volume of 58,990. It is down -0.84% in the last 24 hours and down -15.53% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Previous Close:

$2.99

Open:

$3.02

24h Volume:

58,990

Relative Volume:

0.04

Market Cap:

$162.36M

Revenue:

$2.81M

Net Income/Loss:

$-97.34M

P/E Ratio:

-1.6472

EPS:

-1.8

Net Cash Flow:

$-91.47M

1W Performance:

-10.69%

1M Performance:

-15.53%

6M Performance:

-61.19%

1Y Performance:

-32.46%

1-Day Range:

$2.955

$3.06

1-Week Range:

$2.86

$3.30

52-Week Range:

$2.86

$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2024-11-05

Latest SEC Filings

FULC's Discussions on Twitter

Compare FULC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FULC	2.965	162.36M	2.81M	-97.34M	-91.47M	-1.80
VRTX	445.00	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	736.17	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	583.62	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.09	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.19	24.49B	3.30B	-501.07M	1.03B	11.54

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

Nov 20, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Nov 20, 2024

Nov 19, 2024

Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail

Nov 19, 2024

Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 18, 2024

Research Analysts Issue Forecasts for FULC FY2024 Earnings - MarketBeat

Nov 18, 2024

Nov 15, 2024

Simplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 15, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 14, 2024